{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:58:57Z","timestamp":1777453137030,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"6-8","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside\/nucleotide reverse transcriptase inhibitors (NRTIs) in human immunodeficiency virus (HIV)\u2013infected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      RPV-treated HIV-infected patients from phase 2b or 3 studies rolled-over into this phase 3, open-label study and received RPV 25\u00a0mg once daily (QD) with choice of two NRTIs. Adverse events (AEs), plasma viral load, CD4\n                      <jats:sup>+<\/jats:sup>\n                      cell count, and antiviral resistance were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 482 patients treated, 437 (&gt;90%) patients discontinued study treatment; 371 (77%) had switched to commercially available RPV, 14 (2.9%) discontinued due to AEs, and 6 (1.2%) had virologic failure. In this rollover study, patients were followed up to week 336, although data was limited beyond 288\u00a0weeks. Forty-five (9.3%) patients were still undergoing treatment at the time of data cut-off for the current analysis (8 February 2018). The most frequently reported AEs were pregnancy in 7 (1.5%) patients and syphilis in 5 (1.0%) patients. Grade 3\u20134 AEs were reported in 17 (3.5%) patients, and AEs possibly related to RPV in 23 (4.8%) patients. Over 288\u00a0weeks of treatment, 80.1% (95% CI: 74.9%; 84.3%) of patients maintained virologic suppression (HIV-1 RNA &lt;50 copies\/mL). The absolute CD4\n                      <jats:sup>+<\/jats:sup>\n                      cell count increased over time until week 192 and remained constant thereafter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RPV 25\u00a0mg QD in combination with an investigator-selected background regimen of two NRTIs demonstrated sustained long-term virologic suppression. The treatment was well-tolerated with no new safety findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535211062388","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T23:05:47Z","timestamp":1637967947000},"page":"95-105","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and efficacy of rilpivirine in combination with nucleoside\/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies"],"prefix":"10.1177","volume":"26","author":[{"given":"Jean Michel","family":"Molina","sequence":"first","affiliation":[{"name":"University of Paris, Department of Infectious Diseases, St-Louis and Lariboisi\u00e8re hospitals, APHP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Ene","sequence":"additional","affiliation":[{"name":"Spitalul de Boli Infectioase si Tropicale \"Dr. Victor Babes\" Bucuresti, Sos, Bucuresti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[{"name":"Fundacion Huesped, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cologne, KerpenerStra\u00dfe, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Wijngaerden","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Lombaard","sequence":"additional","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Zakharova","sequence":"additional","affiliation":[{"name":"Centre for Prophylaxis and Control of AIDS and Infectious Diseases, St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Turnhoutseweg, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Turnhoutseweg, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Turnhoutseweg, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"bibr1-13596535211062388","volume-title":"Global HIV & AIDS Statistics \u2014 2019 Fact Sheet","author":"UNAIDS","year":"2019"},{"key":"bibr2-13596535211062388","volume-title":"European Guidelines for the Treatment of HIV-Positive Adults in Europe","author":"EACS","year":"2019"},{"key":"bibr3-13596535211062388","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"USDHHS","year":"2019"},{"key":"bibr4-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31891-9"},{"key":"bibr5-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31311-4"},{"key":"bibr6-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32297-3"},{"key":"bibr7-13596535211062388","volume-title":"Highlights of Prescribing Information","author":"EDURANT\u00ae","year":"2011"},{"key":"bibr8-13596535211062388","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.M17000005"},{"key":"bibr9-13596535211062388","volume-title":"Highlights of Prescribing Information","author":"COMPLERA\u00ae","year":"2011"},{"key":"bibr10-13596535211062388","volume-title":"Highlights of Prescribing Information","author":"ODEFSEY\u00ae","year":"2016"},{"key":"bibr11-13596535211062388","volume-title":"Highlights of Prescribing Information","author":"JULUCA\u00ae","year":"2017"},{"key":"bibr12-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"bibr13-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"bibr14-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cee6e"},{"key":"bibr15-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0050"},{"key":"bibr16-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833032ed"},{"key":"bibr17-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171227"},{"key":"bibr18-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.01.012"},{"key":"bibr19-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30053-X"},{"key":"bibr20-13596535211062388","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.00991.x"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211062388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535211062388","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211062388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:02Z","timestamp":1777380782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535211062388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":20,"journal-issue":{"issue":"6-8","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1177\/13596535211062388"],"URL":"https:\/\/doi.org\/10.1177\/13596535211062388","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}